根据最新消息,百济神州将在即将举行的2024年第66届美国血液学会(ASH)年会上展示其在研创新药物的临床数据。这一信息引人瞩目,可能为百济神州盘中大跌5.14%的股价提供支撑。
据了解,百济神州将在血液学会年会上展示其针对多种B细胞恶性肿瘤的创新血液学产品组合。其中包括3期SEQUOIA研究5年结果显示所有CLL受试患者均因百悦泽持续获益;BTK嵌合式降解激活化合物BGB-16673良好的安全性和有效性数据;以及BCL2抑制剂sonrotoclax联合百悦泽在治疗初治CLL/SLL患者方面所显示的深度且持久的缓解情况。
这些在研新药的临床进展充分体现了百济神州在创新药物研发上所取得的成果,展示了其在血液学领域的创新实力。相关临床数据的披露有望增强投资者对公司长期发展前景的信心,为百济神州股价带来支撑。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.